CalciMedica
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
505 Coast Blvd S Ste 307, La Jolla, Cali...Phone Number
(858) 952-5500Website
www.calcimedica.comRevenue
<$5 MillionStock Symbol
CALCIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CalciMedica
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Explore more
CalciMedica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CalciMedica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on CalciMedica recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CalciMedica
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once CalciMedica has new funding data
Check out if CalciMedica is spiking on competitors!
Click to see if CalciMedica had a recent Job posting/layoffs
CalciMedica, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when CalciMedica launches new products
Check if CalciMedica has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to CalciMedica
Compare insights from companies similar to CalciMedica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CalciMedica is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CalciMedica is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CalciMedica.
CalciMedica financials insights
Gather financial insights about CalciMedica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$6M
Debt
$4M
2012
Debt
$13.2M
Debt
$4.6M
2013
Debt
$3M
2014
Private Equity
$2.5M
2020
Series C
$15M
2021
Series D
$21M
2026
Stock/Share Issuance
$15M
CalciMedica Tech Stack
A closer look at the technologies used by CalciMedica
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Funding
Funding
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
CalciMedica News & Media
Alafi Capital updates CalciMedica (NASDAQ: CALC) stake after multimillion-warrant grant
Stake totals 7.22M shares and warrants, or 19.9% of CalciMedica. This Form 13D/A shows new Series A and B warrants capped by a 19.99% limit.Major CalciMedica (CALC) holder receives new Series A and B warrants - Stock Titan
Major holder ALAFI CAPITAL CO LLC received Series A and B CalciMedica warrants on Aug. 19, 2026, with strikes at $0.8033 and $1.00, and now holds 5,112,345 shares.CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
CalciMedica, Inc. (NASDAQ:CALC) shares rose 6.CalciMedica (NASDAQ: CALC) narrows year-to-date loss, secures $49M PH financing
CalciMedica reported a Q2 2026 net loss of $7.7M, cut operating expenses to $4.0M, raised up to $49M for pulmonary hypertension programs, and expects its $18.6M cash balance to fund operations into the second half of 2027.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CalciMedica
Sign Up For FreeTo access detailed company insights
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in... Read More
